InPen™ is a prescription-only device. Eligible patients with commercial insurance may pay as little as $35 per prescribed InPen™. Each InPen™ is reusable for one year. Terms and conditions apply.
Smart insulin products
InPen™ smart insulin pen
<p>InPen™ is a smart insulin pen that connects to a mobile app to provide dosing calculations, reminders, and CGM system integration for diabetes patients.</p>
Features
Intuitive decision support
InPen™ helps MDI users take the right amount of insulin at the right time, thanks to real-time tracking and decision support.
Humalog® is a registered trademark of Eli Lilly and Company.
Fiasp® and Novolog® are registered trademarks of Novo Nordisk A/S
InPen™ helps solve common MDI challenges
Missing 2 doses per week can lead to an increase in A1C of up to 0.4%1
2 out of 3 people need help calculating their doses and 60% of doses are stacked2–4
Lack of accurate dosing data is a barrier to optimizing glycemic control5
The use of a bolus calculator is associated with a 0.7–1.0% reduction in A1C6–8
Patient data in one convenient place
Integrated, reliable diabetes data
InPen™ Insights Reports provide a way to view a patient’s glucose, carbohydrate, and insulin dosing data from their InPen system.
Easy collaboration
InPen™ Insights Reports help providers assess a patient’s insulin doses and glycemic levels, regardless of which multiple daily injection regimen the patient is following.
Example patient profile
Offer available to those with commercial insurance.
Terms and conditions apply.
A system that helps make life easier for your patients
InPen helps MDI users take the right amount of insulin at the right time, thanks to real-time tracking and decision support
- Tracks active insulin
- Reminds user to dose
- Calculates personalized doses
- Automatically logs doses
- Syncs with CGMs and glucose meters
Frequently asked questions
If you need help adjusting your patient’s therapy mode (dose calculator) in the InPen app via EMR or call 800-464-4633, option 9, option 1.
Our trained InPen™ specialists are available for virtual 1-on-1 training sessions Monday through Friday from 6 a.m.–6 p.m. PT. We ask that patients contact their healthcare provider with questions about their therapy settings, insulin regimen, or blood glucose concerns.
* Smart insulin pens connect to a mobile app to provide dosing calculations, reminders and CGM system integration.
1. Randlov, J., Poulsen, J.U. J Diabetes Sci Technol. 2008 Mar; 2(2): 229-235. Published online 2008 Mar. doi: [10.1177/1932296 80800200209]
2. Garg SK, Bookout TR, McFann KK, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technology and Therapeutics. 2008; 10(5):369-375.
3. Zaugg, Stephanie D., et al. “Diabetes numeracy and blood glucose control: association with type of diabetes and source of care.” Clinical diabetes: a publication of the American Diabetes Association 32.4 (2014): 152-157.
4. Cavanaugh, Kerri, et al. “Association of numeracy and diabetes control.” Annals of Internal Medicine. 148.10 (2008): 737-746.
5. Klonoff DC, Kerr D. Smart Pens Will Improve Insulin Therapy. J Dia Sci & Tech. 2018;12(3):551-553.
6. Ziegler R, Cavan DA, Cranston I, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013; 36(11):3613-3619.
7. Kaufman FR, Halvorson M, Carpenter S. Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care. 1999; 22(8):1252-1257.
8 Anderson DG. Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII. Pediatric Diabetes. 2009; 10(5):304-309.